AbbVie v. Amgen Round One: Humira Biosimilar Infringes 10 Patents, Suit Claims

'Amgen is speaking out of both sides of its mouth', AbbVie contends, promising suit on dozens more patents.

court house

AbbVie Inc.'s patent infringement suit against Amgen Inc. over its proposed biosimilar to Humira (adalimumab) may provide the most complete picture yet of what "patent dance"-choreographed litigation could look like, but the complaint also contends that Amgen has not provided full information about its manufacturing process.

The suit, filed Aug. 4 in the U.S. District Court for the District of Delaware, claims Amgen's product...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Biosimilars

More from Biosimilars & Generics